BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION

BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION

The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the fun...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MITTELHOLZER, Christian, KIPFER, Enja Tatjana, KLIMKAIT, Thomas, OTTE, Fabian
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MITTELHOLZER, Christian
KIPFER, Enja Tatjana
KLIMKAIT, Thomas
OTTE, Fabian
description The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-CoV-2.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2022341555A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2022341555A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2022341555A13</originalsourceid><addsrcrecordid>eNrjZLB08vT38Xf3dHb08YlUCAjydwl1dnVR8At19nH1dFZwdPZ0UXDzD1IIc3R29vRzhaoI8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8Y6hRgZGRsYmhqampo6GxsSpAgAjIyl1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION</title><source>esp@cenet</source><creator>MITTELHOLZER, Christian ; KIPFER, Enja Tatjana ; KLIMKAIT, Thomas ; OTTE, Fabian</creator><creatorcontrib>MITTELHOLZER, Christian ; KIPFER, Enja Tatjana ; KLIMKAIT, Thomas ; OTTE, Fabian</creatorcontrib><description>The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-CoV-2.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240118&amp;DB=EPODOC&amp;CC=AU&amp;NR=2022341555A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240118&amp;DB=EPODOC&amp;CC=AU&amp;NR=2022341555A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MITTELHOLZER, Christian</creatorcontrib><creatorcontrib>KIPFER, Enja Tatjana</creatorcontrib><creatorcontrib>KLIMKAIT, Thomas</creatorcontrib><creatorcontrib>OTTE, Fabian</creatorcontrib><title>BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION</title><description>The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-CoV-2.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB08vT38Xf3dHb08YlUCAjydwl1dnVR8At19nH1dFZwdPZ0UXDzD1IIc3R29vRzhaoI8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8Y6hRgZGRsYmhqampo6GxsSpAgAjIyl1</recordid><startdate>20240118</startdate><enddate>20240118</enddate><creator>MITTELHOLZER, Christian</creator><creator>KIPFER, Enja Tatjana</creator><creator>KLIMKAIT, Thomas</creator><creator>OTTE, Fabian</creator><scope>EVB</scope></search><sort><creationdate>20240118</creationdate><title>BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION</title><author>MITTELHOLZER, Christian ; KIPFER, Enja Tatjana ; KLIMKAIT, Thomas ; OTTE, Fabian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2022341555A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MITTELHOLZER, Christian</creatorcontrib><creatorcontrib>KIPFER, Enja Tatjana</creatorcontrib><creatorcontrib>KLIMKAIT, Thomas</creatorcontrib><creatorcontrib>OTTE, Fabian</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MITTELHOLZER, Christian</au><au>KIPFER, Enja Tatjana</au><au>KLIMKAIT, Thomas</au><au>OTTE, Fabian</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION</title><date>2024-01-18</date><risdate>2024</risdate><abstract>The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-CoV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-CoV-2.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2022341555A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T11%3A26%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MITTELHOLZER,%20Christian&rft.date=2024-01-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2022341555A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true